成人ALL完全缓解三年后仍存在复发风险:MRC UKALLXII/ECOG E2993研究
该研究基于MRC UKALLXII/ECOG E2993试验中1909例成人急性淋巴细胞白血病(ALL)患者,评估晚期复发(完全缓解后超过3年)的发生率与特征。晚期复发者复发后生存优于早期复发者。
核心结论
- 成人ALL晚期复发并不少见,且复发后结局优于早期复发。
研究设计与样本
- 国际多中心MRC UKALLXII/ECOG E2993试验数据,纳入1909例成人ALL患者。
临床怎么用
- 成人ALL达完全缓解3年后仍需关注复发风险,长期随访中应保持警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37-144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five-year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse.
引用
- Ganzel C, Wang XV, Rowe JM, et al. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. Br J Haematol. 2020. PMID: 32220069. doi:10.1111/bjh.16616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。